TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GSK

GSK

GSK plc

Next earnings Jul 28, 2026 · consensus $0.46 EPS, $8.48B rev

Sell
$53.66
▲ +1.61%
$53.66▲ +44.30%
over 1Y
L $34.89H $60.14
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.6%
1W+3.4%
1M+9.5%
3M-4.5%
YTD+10.0%
1Y+44.3%
OverviewValuationQualityFilings
Rating
Sell
Quality
B
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 32 analysts
Buy

Mixed signals in the latest filings.

GSK plc shows limited reported revenue.

On these fundamentals, GSK screens as SELL on the SEC figures.

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:17 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$107B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-07-012026-07-01open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-262026-06-26open ↗SC TO-T/AFiling2026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗SC TO-TFiling2026-06-24open ↗6-KPeriod ending 2026-06-232026-06-23open ↗6-KPeriod ending 2026-06-222026-06-22open ↗11-KPeriod ending 2025-12-312026-06-17open ↗11-KPeriod ending 2025-12-312026-06-17open ↗

Quality score

B
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumB
34.8952-week60.14
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is GSK plc (GSK) a buy?
GSK currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is GSK plc's quality score?
GSK scores 73.63893094950396/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001131399, latest 6-K filed 2026-07-01) · EODHD · as of 7/4/2026, 2:17:37 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-12-11
GSK plc
10% owner
Buy1.47M @ $19.00$27.9M
2024-09-27
GSK plc
10% owner
Buy2.79M @ $8.00$22.3M
2023-12-07
GSK plc
10% owner
Buy3.30M @ $5.00$16.5M
2022-09-16
GSK PLC
Insider
Disposed (J)9.64M @ $9.75$94.0M

Dividends

Quarterly
Yield (TTM)
3.3%
Annual / share
$1.79
Last ex-date
2026-05-15
Last amount
$0.46
ex 2026-05-15paid 2026-07-09$0.46
ex 2026-02-20paid 2026-04-09$0.49
ex 2025-11-14paid 2026-01-08$0.42
ex 2025-08-15paid 2025-10-09$0.43
ex 2025-05-16paid 2025-07-10$0.43
ex 2025-02-21paid 2025-04-10$0.40

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Congressional trades

all activity →

Disclosed under the STOCK Act

2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-10-10Valerie HoyleSell$1.00K–$15.0KPTR ↗
2025-09-12Valerie HoyleBuy$1.00K–$15.0KPTR ↗
2025-09-12Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-09-10Robert B. AderholtSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-05-12Bruce WestermanSell$1.00K–$15.0KPTR ↗
2025-04-16Bruce WestermanBuy$1.00K–$15.0KPTR ↗
2024-11-27Marjorie Taylor Mrs GreeneBuy$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?Bullish
nasdaq.com· 2026-07-03
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?Bullish
finance.yahoo.com· 2026-07-03
Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock.Bullish
finance.yahoo.com· 2026-07-02
FTSE 100 rises as US jobs data eases Fed rate hike fearsBullish
uk.finance.yahoo.com· 2026-07-02
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per ShareBullish
finance.yahoo.com· 2026-06-30
Big Pharma Has a Case of Merger ManiaBullish
nasdaq.com· 2026-06-30

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score74 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 43d
Bullish
+0.14
vs typical · 113 articles

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.